Triumph Capital Management’s Genmab GMAB Stock Holding History

Triumph Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$192	Hold	7	–	–	﹤0.01%	1802
2026 Q1	$188	Buy	+7	New	+$210	﹤0.01%	1769

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Triumph Capital Management's GMAB Position: Q2 2026 in Review

Triumph Capital Management held its Genmab (GMAB) position steady in Q2 2026 at 7 shares worth $192. The position accounts for ﹤0.01% of the portfolio, ranked #1802.

Triumph Capital Management first reported a position in GMAB in Q1 2026 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

Triumph Capital Management held 7 shares of Genmab worth $192 as of Q2 2026.
Triumph Capital Management left its Genmab share count unchanged in Q2 2026.
Genmab made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1802 holding.
Triumph Capital Management first reported a position in Genmab in Q1 2026 and has held it in 2 quarters since.
289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.